<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172753</url>
  </required_header>
  <id_info>
    <org_study_id>659/2017BO1</org_study_id>
    <nct_id>NCT04172753</nct_id>
  </id_info>
  <brief_title>Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac</brief_title>
  <official_title>Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac
      radiotherapy hybrid device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novel hybrid devices combine magnetic resonance imaging (MRI) and a linear accelerator in a
      single device. The superior soft tissue contrast compared with cone-beam computed tomography
      based treatment and the possibility for daily plan adaptation promise a higher precision of
      treatment, better target volume coverage and normal tissue sparing. In a first step the
      present study will test the feasibility of imaging and treatment on the 1.5 T MR-Linac.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">May 9, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of online MR guided Radiotherapy</measure>
    <time_frame>During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)</time_frame>
    <description>Treatment of a patient is considered feasible when 85% of treatments were completed as planned in this patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time analysis</measure>
    <time_frame>During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)</time_frame>
    <description>Time required for online MR guided radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Oligometastasis</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Rectal and anal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with rectal and anal cancer are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with prostate cancer are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with head and neck cancers are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with esophageal cancer are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with breast cancer are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central nervous system tutors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with tumors of the central nervous system are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palliative treatments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with palliative treatments are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients with other tumors are recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients receive only imaging on the MR-Linac</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy on the MR-Linac</intervention_name>
    <description>Radiotherapy is performed on the 1.5 T MR Linac</description>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_label>Central nervous system tutors</arm_group_label>
    <arm_group_label>Esophageal cancer</arm_group_label>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_label>Other</arm_group_label>
    <arm_group_label>Palliative treatments</arm_group_label>
    <arm_group_label>Prostate cancer</arm_group_label>
    <arm_group_label>Rectal and anal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging on the MR Linac</intervention_name>
    <description>Only imaging performed on the MR Linac</description>
    <arm_group_label>Imaging only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  existing indication for radiation therapy

          -  minimum age 18 years, no upper age limit

          -  capacity for consent

          -  Informed consent

        Exclusion Criteria:

          -  contraindication for MRI (claustrophobia, metallic implants not applicable for MRI

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Tübingen, Department of Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zips, MD, Prof</last_name>
      <phone>+49 (0) 7071 29-85990</phone>
      <email>ro-info@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Cihan Gani, MD</last_name>
      <phone>+49 (0)7071 29-82165</phone>
      <email>cihan.gani@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Cihan Gani</investigator_full_name>
    <investigator_title>Lead of gastrointestinal radiation oncology</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Adaptive Radiotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

